Ryvu Therapeutics has a track record of creating significant value for shareholders since its listing on the NewConnect market in 2011 and the subsequent IPO on the main market of Warsaw Stock Exchange in 2014. The company has delivered strong return on the combined $55M investment from private, public market investors, demonstrating research progress, bringing novel drug candidates to the clinic and additionally raising over $50M in non-dilutive grant funding to support its research efforts.

We value investor communications very highly and we build our investor relationships on trust and transparency. Ryvu is audited by EY and is subject to regulatory oversight of the Polish Financial Supervisory Authority, under the European Union and the Polish laws. Ryvu technological expertise is validated by global partnerships with Merck KGaA, Menarini Group and Leukemia & Lymphoma Society.

In 2016 Ryvu has spun out its NALP3 inflammasome assets to NodThera financed by Epidarex Venture Capital. In 2018 Sofinnova, 5AM Ventures, F-Prime and Epidarex have invested $40 M Series A in NodThera and Ryvu remains a shareholder in the company. For more information about NodThera see: www.nodthera.com.

Ryvu Milestones

2007
2010
2011
2013
2014
2015
2016
2017
2019

2007

  • Company founded (as Selvita)

2010

  • First global partnering contract with Orion Pharma (as Selvita S.A.)

2011

  • Listed on NewConnect market (WSE)

2013

  • Beginning of oncology partnership with Merck KGaA

2014

  • IPO on Warsaw Stock Exchange

2015

  • Spin-out of Ardigen – precision medicine & AI services company

2016

  • Inflammasome assets spun-out to Nodthera

2017

  • Initiation of SEL24/MEN1703 study in acute myeloid leukemia
  • Global license agreement with Menarini Group for SEL24/MEN1703
  • Partnership with the Leukemia & Lymphoma society for SEL120 development

2019

  • Ryvu divests its CRO business into Selvita
  • Initation of SEL120 study in acute myeloid leukemia or high-risk myelodysplastic syndromes

Contact For Investors

;